Vivex Biologics operates in biotechnology. Its shares do not trade on a public exchange.
Vivex Biologics has no published valuation.
VIVEX Biologics develops and distributes human cells, tissues, and cellular and tissue-based products, treating patients with musculoskeletal injuries, wounds and burned skin. Its product lines include amniotic membrane allografts in single-, dual- and multi-layer configurations and demineralized bone matrix products such as putties, sponges and fibers, distributed to hospitals and approved resellers.
Based in Miami, Florida, the company traces its history back to 1970 and processes tissue in compliance with FDA and AATB standards. VIVEX also runs internal research and development to create new allografts and manufacturing methods, and it works with accredited recovery organizations that perform tissue recoveries under aseptic surgical protocols.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Vivex Biologics.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Vivex Biologics availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Vivex Biologics included.
The closest biotechnology peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Vivex Biologics is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
